SLC5A2 and kidney disorder: Although heart failure was not the focus of this study, we acknowledge the heightened interest in UACR among this population [22] [23], especially with the emergence of sodium-dependent glucose transporters 2 (SGLT2) inhibitors in treatment regimens for heart failure and kidney disease.